Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bacterial Communities Clear all
Completed Phase 3 Interventional

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 1:52 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 2, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia

NCT01198626
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia (CABP)
Interventions
JNJ-32729463, moxifloxacin, JNJ-32729463 (Open-Label)
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Mobile, Alabama • Sylmar, California • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

NCT02679573
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Delafloxacin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia

NCT00509106
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Ceftaroline fosamil for Injection, Ceftriaxone, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus

NCT01645735
View directory record Official record
Conditions
Infections
Interventions
Ceftaroline fosamil, Ceftriaxone plus vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Sylmar, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Not applicable Interventional Results available

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

NCT00513799
View directory record Official record
Conditions
Abscesses, Furunculosis, Staphylococcus Aureus, Staphylococcal Skin Infections
Interventions
Mupirocin ointment, Chlorhexidine showers, Bleach baths (dilute), Intensive education on personal hygiene
Drug · Genetic · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Not applicable Interventional

Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

NCT05976581
View directory record Official record
Conditions
Pneumonia, Pneumonia, Viral, Pneumonia, Bacterial
Interventions
Electronic alert, Structured communication of test results
Behavioral
Lead sponsor
Jonathan Baghdadi
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

NCT02813694
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Beverly Hills, California • Fresno, California • Northridge, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2015 · Synced Sep 2, 2026, 1:52 AM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 4 Interventional

Washington State Community Expedited Partner Treatment (EPT) Trial

NCT01665690
View directory record Official record
Conditions
Gonorrhea, Neisseria Gonorrhoeae, Chlamydia Trachomatis
Interventions
Patient delivered partner therapy, Targeted public health partner services
Other · Behavioral
Lead sponsor
University of Washington
Other
Eligibility
14 Years and older
Enrollment
33,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Olympia, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Sep 2, 2026, 1:52 AM EDT
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

NCT02663674
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Fluconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438
View directory record Official record
Conditions
Bacterial Pneumonia, Community-Acquired Infections
Interventions
Omadacycline, Moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 2, 2026, 1:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sources of Bacterial Contamination in Human Milk Samples From the MiLC Trial

NCT03371511
View directory record Official record
Conditions
Bacterial Communities
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Study of Fluid Collection of the Chest in Children With Pneumonia

NCT00202826
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia, Paraneumonic Effusion
Interventions
Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage
Procedure
Lead sponsor
Corewell Health West
Other
Eligibility
0 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Sep 2, 2026, 1:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Vaginal Microbiota Transplant

NCT04046900
View directory record Official record
Conditions
Recurrent Bacterial Vaginosis
Interventions
Vaginal microbiome transplant, Oral Metronidazole, Sterile saline
Biological · Drug · Other
Lead sponsor
Douglas Kwon
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01756339
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin, Placebo to match solithromycin
Drug · Other
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Glendale, California • Los Angeles, California • Mission Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

NCT02559310
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hazard, Kentucky • Shreveport, Louisiana • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 2, 2026, 1:52 AM EDT
Completed No phase listed Observational

Etiology of Community Acquired Pneumonia

NCT00471757
View directory record Official record
Conditions
Streptococcus Pneumonia, Haemophilus Influencae, Mycoplasma Pneumonia, Chlamydia Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 3 Interventional

Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia

NCT01605864
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Efficacy of ceftaroline
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 2, 2026, 1:52 AM EDT
Completed No phase listed Observational Results available

Molecular Epidemiology of Clostridium Difficile Infections in Children

NCT01957761
View directory record Official record
Conditions
Clostridium Difficile Infections
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Year to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 2, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

NCT00797108
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
Sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Chula Vista, California • Oceanside, California • Moline, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Sep 2, 2026, 1:52 AM EDT